Clinical response to ustekinumab in CARD14-associated papulosquamous eruption (cape) with a new missense mutation in CARD14: A case report and sistematic review.

The term CAPE was first introduced by Craiglow et al(1) to define a papulosquamous eruption due to mutations in CARD14 in patients that display characteristics of both psoriasis and pityriasis rubra pilaris (PRP). Heterozygous mutations in CARD14 have been described in psoriasis(2) and PRP(3,4) patients, indicating that these disorders share a common underlying pathophysiology.